%0 Journal Article
%T Evaluation of Efficacy and Safety of Platelet-Rich Plasma Eye Drops in Patients with Dry Eye Syndrome
%A Li Huang
%A Bin Wu
%A Jing Mao
%A Liping Peng
%A Xiaoqin Liu
%A Min Wang
%J Journal of Biosciences and Medicines
%P 12-18
%@ 2327-509X
%D 2025
%I Scientific Research Publishing
%R 10.4236/jbm.2025.136002
%X <b>Objective:</b> To explore the clinical efficacy and safety of autologous platelet-rich plasma (PRP) eye drops in treating moderate to severe dry eye syndrome (SS). <b>Method:</b> A prospective randomized controlled study was conducted, including 60 patients with SS and moderate to severe dry eye syndrome admitted to the First People&#8217;s Hospital of Jingzhou from May 2024 to May 2025. The patients were randomly divided into the PRP group (n = 30) and the control group (n = 30). The PRP group received autologous PRP eye drops, while the control group used 0.3% sodium hyaluronate eye drops, both administered three times daily for one month. The primary outcome measures included changes in the Schirmer test, tear film break-up time (BUT), and corneal conjunctival fluorescein staining (CFS) scores before and after treatment, along with recording any adverse reactions. <b>Results: </b>After treatment, the PRP group showed significantly better Schirmer test values (6.8 &#177; 1.5 mm vs 4.5 &#177; 1.2 mm) and BUT (8.2 &#177; 1.2s vs 5.0 &#177; 0.9 s) compared to the control group, with a significant decrease in CFS scores (3.1 &#177; 0.8 vs 5.2 &#177; 1.3) (all P &lt; 0.05). There was no statistically significant difference in adverse reaction rates between the two groups (13.3% vs 10.0%, P &gt; 0.05). <b>Conclusion:</b> Autologous PRP eye drops can effectively improve dry eye symptoms in SS patients, promote ocular surface repair, and have good safety and clinical application value.
%K Sjogren&#8217
%K s Syndrome
%K Dry Eye
%K Platelet-Rich Plasma
%K Eye Drops
%K Efficacy
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=143103